BIOVENTIX PLC Logo

BIOVENTIX PLC

BVXP | IL

Overview

Corporate Details

ISIN(s):
GB00B4QVDF07
LEI:
213800225MHX7LZQY108
Country:
United Kingdom
Address:
7 ROMANS BUSINESS PARK, GU9 7SX FARNHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bioventix PLC is a biotechnology company specializing in the development and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized as critical components in clinical diagnostic applications, primarily for automated immunoassays used in blood testing. The company supports healthcare organizations by creating novel SMAs, with a development timeline of approximately nine months from initial immunisation to the delivery of purified antibodies for evaluation. Its product portfolio includes a range of SMAs for the global clinical diagnostics market and ELISA kits designed to monitor exposure to industrial pollutants. The company's antibodies are instrumental in various diagnostic areas, including troponin assays for assessing cardiac conditions and research into neurological disorders like Alzheimer's disease.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for BIOVENTIX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 15:19
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-04-28 18:13
Director's Dealing
Director Dealing
English 19.8 KB
2025-03-31 08:00
Interim Report
Interim Results
English 106.1 KB
2024-12-24 10:14
Director's Dealing
Director Dealing
English 19.3 KB
2024-12-06 08:00
Post-Annual General Meeting Information
Result of AGM
English 8.1 KB
2024-12-04 16:34
Major Shareholding Notification
Holding(s) in Company
English 52.9 KB
2024-11-22 16:56
Director's Dealing
Director/PDMR Shareholding
English 19.5 KB
2024-11-08 08:57
Report Publication Announcement
Notice of AGM
English 8.1 KB
2024-10-31 08:00
Director's Dealing
Director/PDMR Shareholding
English 19.2 KB
2024-10-28 08:00
Annual / Quarterly Financial Statement
Results for the year ended 30 June 2024
English 442.9 KB
2024-10-25 11:37
Major Shareholding Notification
Holding(s) in Company
English 31.1 KB
2024-10-16 14:51
Major Shareholding Notification
Holding(s) in Company
English 43.9 KB
2024-04-30 08:00
Director's Dealing
Director/PDMR Shareholding
English 19.2 KB
2024-04-12 12:05
Major Shareholding Notification
Holding(s) in Company
English 53.7 KB
2024-03-25 08:00
Interim Report
Interim Results
English 144.5 KB

Automate Your Workflow. Get a real-time feed of all BIOVENTIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BIOVENTIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Otsuka Holdings Co., Ltd. Logo Japan 4578
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
PAION AG Logo
Developed innovative drugs for hospital sedation, anesthesia, and critical care.
Germany PA8
PeptiDream Inc. Logo Japan 4587
PEPTONIC Medical AB Logo
Develops clinically proven self-care products and diagnostics for women's intimate health.
Sweden PMED
Perseus Proteomics Inc. Logo Japan 4882
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain PHM
Pharmanutra Logo
Develops science-backed nutraceuticals & pharmaceuticals for nutritional & joint health.
Italy PHN
PharmaSGP Holding SE Logo
Develops & distributes natural, pharmacy-exclusive OTC drugs for chronic conditions in Europe.
Germany PSG
Pharmena S.A. Logo
Develops patented 1-MNA molecule for dermocosmetics and supplements in EU & North American markets.
Poland PHR